Literature DB >> 21180645

Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease.

O K Sujith1, Carol Lane.   

Abstract

Treatment of Parkinson's disease aims to replace dopaminergic transmission at striatal synapses. In the normal state, nigral neurons fire continuously, exposing striatal dopamine receptors to relatively constant levels of dopamine. In the disease state, periodic dosing and the short half-life of antiparkinsonian drugs leads to more intermittent stimulation. Abnormal pulsatile stimulation of striatal dopamine receptors may lead to dysregulation of genes and proteins in downstream neurons and consequently, alterations in neuronal firing patterns. This may ultimately lead to motor complications. In order to prevent the development of motor complications a therapy that provides continuous dopaminergic stimulation as observed in the normal state would be ideal. Different routes of administration of levodopa and other dopaminergic drugs have been tried to achieve continuous dopaminergic stimulation (CDS). This review discusses the various methods available to achieve this goal with particular emphasis on duodenal dopa administration.

Entities:  

Keywords:  continuous dopaminergic stimulation; intraduodenal administration; levodopa; parkinsonism

Year:  2009        PMID: 21180645      PMCID: PMC3002621          DOI: 10.1177/1756285608101378

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  76 in total

Review 1.  The functional anatomy of disorders of the basal ganglia.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1995-02       Impact factor: 13.837

2.  Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.

Authors:  N Syed; J Murphy; T Zimmerman; M H Mark; J I Sage
Journal:  Mov Disord       Date:  1998-03       Impact factor: 10.338

3.  Duodenal levodopa infusion in Parkinson's disease--long-term experience.

Authors:  D Nilsson; D Nyholm; S M Aquilonius
Journal:  Acta Neurol Scand       Date:  2001-12       Impact factor: 3.209

4.  Gastric emptying time and gastric motility in patients with Parkinson's disease.

Authors:  R Hardoff; M Sula; A Tamir; A Soil; A Front; S Badarna; S Honigman; N Giladi
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

5.  Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Authors:  R Pahwa; M A Stacy; S A Factor; K E Lyons; F Stocchi; B P Hersh; L W Elmer; D D Truong; N L Earl
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

6.  Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.

Authors:  F Stocchi; S Ruggieri; A Carta; J Ryatt; N Quinn; P Jenner; C D Marsden; A Agnoli
Journal:  Mov Disord       Date:  1992       Impact factor: 10.338

Review 7.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease.

Authors:  Frédéric Calon; Ali H Rajput; Oleh Hornykiewicz; Paul J Bédard; Thérèse Di Paolo
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

Review 9.  [Apomorphine in off state--clinical experience].

Authors:  Monika Rudzińska; Andrzej Szczudlik
Journal:  Neurol Neurochir Pol       Date:  2007 Mar-Apr       Impact factor: 1.621

Review 10.  Rotigotine transdermal system for the treatment of Parkinson's disease.

Authors:  David Q Pham; Anna Nogid
Journal:  Clin Ther       Date:  2008-05       Impact factor: 3.393

View more
  6 in total

1.  Placement of the AbbVie PEG-J tube for the treatment of Parkinson's disease in the interventional radiology suite.

Authors:  Mark L Montgomery; Noel K Miner; Michael J Soileau; Douglas K McDonald
Journal:  Proc (Bayl Univ Med Cent)       Date:  2016-10

Review 2.  Targeting heat shock proteins to modulate α-synuclein toxicity.

Authors:  Daryl Rhys Jones; Simon Moussaud; Pamela McLean
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

3.  Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.

Authors:  Aiping Wang; Lexi Wang; Kaoxiang Sun; Wanhui Liu; Chunjie Sha; Youxin Li
Journal:  Pharm Res       Date:  2012-05-02       Impact factor: 4.200

4.  Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson's disease and its evolution study.

Authors:  Aiping Wang; Yanxiang Liu; Rongcai Liang; Xuemei Zhang; Kaoxiang Sun; Zimei Wu; Wanhui Liu
Journal:  Saudi Pharm J       Date:  2016-05-05       Impact factor: 4.330

5.  Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa.

Authors:  Cindy Zadikoff; Werner Poewe; James T Boyd; Lars Bergmann; Horia Ijacu; Pavnit Kukreja; Weining Z Robieson; Janet Benesh; Angelo Antonini
Journal:  Parkinsons Dis       Date:  2020-02-13

6.  DOPA-sparing strategy in the treatment of young onset Parkinson's disease.

Authors:  Abdul Qayyum Rana; Mohamad Saleh; Muhammad Saad Yousuf; Wasim Mansoor; Syed Hussaini; Maniza Rahman; Zohair Iqbal
Journal:  J Neurosci Rural Pract       Date:  2016 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.